VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals.
Human Longevity (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. Its business areas include the HLI Health Nucleus, a genomic powered clinical research center that uses whole-genome sequence analysis, advanced clinical imaging, and innovative machine learning, along with curated personal health information to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. It was founded in 2013 and is headquartered in San Diego, California.
CASI Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and advancing various pharmaceutical products. Among its offerings, EVOMELA is notable for its role as a conditioning treatment prior to autologous stem cell transplants in multiple myeloma patients, while its portfolio also includes CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. CASI Pharmaceuticals primarily generates revenue through the sales of EVOMELA, and it aims to establish itself as a leader in the biopharmaceutical sector by leveraging its expertise in drug development and regulatory processes, particularly in the China market.
Eos BioInnovation is an investment firm focused on launching and developing start-ups in the field of regenerative medicine. The firm specializes in transforming innovative concepts into viable businesses by incubating and supporting early-stage companies that emerge from leading academic laboratories and research institutions. Eos BioInnovation aims to foster a strong track record of success for its clients by facilitating the development of therapies and technologies in regenerative medicine.
Actym Therapeutics is a biotechnology company based in Berkeley, California, dedicated to developing innovative immuno-oncology therapies for cancer treatment. Founded in 2017, the company has created a unique therapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy), which uses an attenuated microbial approach to target solid tumors while sparing healthy tissue. This platform allows for the delivery of multiple immuno-modulatory payloads directly to immune cells residing within tumors, addressing challenges faced by traditional therapies. In preclinical studies, STACT has shown promise in enhancing treatment efficacy by engaging various biological pathways from a single therapy. The company successfully secured $34 million in a Series A financing round in April 2020, which was co-led by prominent venture funds, highlighting its potential in the biopharmaceutical landscape.
Chime Biologics, is a world-class experienced Contract Development and Manufacturing Organization (CDMO), providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. We provide a comprehensive solution supporting our customers from analytical and process transfer to early-stage biopharmaceutical development through late-stage clinical and commercial drug substance and drug product manufacturing for Global Supply.
Base Therapeutics offers cell and gene editing technology designed to treat cancerous diseases. The company's technology includes a natural killer cell genetic engineering platform and other cell therapy products for treatments of lung cancer, liver cancer, glioma, and other hematological tumors
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardio-metabolic diseases. The company aims to enhance patient care for individuals with metabolic disorders by addressing the shortcomings of currently available treatments. Its leading product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to effectively lower LDL cholesterol levels while potentially overcoming the limitations associated with existing therapies.
Coastar Therapeutics is a biotechnology company based in San Diego, California, focused on developing a novel drug delivery platform that utilizes erythrocyte enveloped virus technology. This platform is designed for repeated dosing of oncolytic viruses while evading the immune system's recognition and response, which is a common challenge in systemic drug therapies. By employing human cell lipids with self-identifying motifs, Coastar's technology protects the therapeutic virus from neutralizing antibodies and immune cells, ensuring effective delivery to tumor sites for cancer treatment and immunotherapy. Founded in 2017, the company is also working on expanding its ELCV solutions to address other therapeutic areas, while its unique process technology offers advantages in mass production and cost efficiency.
Jade Biomedical provides regulatory and analytical testing services to biopharmaceutical companies worldwide. It is the world's first registered biologics contract organisation, Bio-CQOR. JADE's founder and leaders have extensive drug agency experience, including NMPA, FDA, EMA, PMDA, and PICS. Their expertise covers all therapeutic platforms, including monoclonal antibodies, antibody-drug-conjugates, cell and gene therapies.
HanchorBio is a biotechnology research firm focused on developing innovative treatments for cancer. The company specializes in drug discovery that leverages tumor immunology, aiming to enhance the quality of life for cancer patients. By concentrating on cutting-edge research and development, HanchorBio seeks to revolutionize cancer treatment through its commitment to advancing therapeutic options.
FineImmu produces cell therapy drugs and immunodiagnostic products. The drug predicts the anti-tumor immune function of PD-1 and PD-L1 and the therapeutic effect of immune checkpoint inhibitors such as CTLA4. The company's contact modes are by phone and physical address.
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.
GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process.
Harvest Integrated Research Organization (HiRO) is a clinical research organization (CRO) that operates on a global scale, offering a comprehensive suite of services to biotechnology and pharmaceutical companies. HiRO specializes in early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, and project management. The organization is committed to collaborating with its clients to facilitate the development and market introduction of new therapeutic products. By focusing on integrated solutions, HiRO aims to enhance the efficiency and effectiveness of drug development processes, ultimately delivering more accessible and cost-effective therapies to patients worldwide.
Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.
Yizun Biotechnology is a cutting-edge immune cell therapy company that has developed many unique platform technologies, including solid tumor treatment and allogeneic universal cell therapy.
TaiLai Biosciences is a biotechnology company based in Shanghai, China, focused on advancing cancer research through its proprietary multiomics technology. The company specializes in developing non-invasive cancer screening and analysis methods, which facilitate a deeper understanding of cancer development and aid in the creation of immune-guided therapies. TaiLai Biosciences offers a range of biopsy products and services that leverage extensive biological data, including DNA, RNA, proteins, and metabolic small molecules. By utilizing bioinformatics and computational science, the company aims to uncover correlations within this complex biological information, ultimately enhancing the effectiveness of cancer diagnosis and treatment.
VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals.
TriArm Therapeutics is a cell therapy company established by Panacea Venture, with research and development operations in Germany, the United States, and the Greater China region. The company specializes in the research and clinical development of CD19 CAR-T products, utilizing non-viral gene transfer technology. This innovative approach significantly lowers both the cost and preparation time associated with cell therapy products, ultimately aiming to enhance therapeutic outcomes for cancer patients.
Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based company specializing in the research and pre-clinical development of therapies for immunology-related conditions. Founded in 2019, it focuses on addressing unmet medical needs globally through a unique approach termed "Borderless Innovation." The company is developing a pipeline of drug candidates, including IMG-020, a protein drug designed to target IL-17A, utilizing advanced technologies that enhance potency and extend the drug's half-life. Inmagene aims to create a new generation of therapeutics characterized by improved pharmacokinetics, pharmacodynamics, and safety profiles, which may lead to better efficacy and dosing convenience. With additional offices in Hangzhou and Beijing, Inmagene is committed to leveraging innovative resources and processes to facilitate drug development across borders, thereby enhancing the potential for positive patient outcomes worldwide.
Chime Biologics, is a world-class experienced Contract Development and Manufacturing Organization (CDMO), providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. We provide a comprehensive solution supporting our customers from analytical and process transfer to early-stage biopharmaceutical development through late-stage clinical and commercial drug substance and drug product manufacturing for Global Supply.
Maestro Surgical is a platform for medical surgical robotics technology.
Innovative Rehabilitation Equipment Company that Helps Mobility-Impaired Patients to Regain Walking Ability
Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based company specializing in the research and pre-clinical development of therapies for immunology-related conditions. Founded in 2019, it focuses on addressing unmet medical needs globally through a unique approach termed "Borderless Innovation." The company is developing a pipeline of drug candidates, including IMG-020, a protein drug designed to target IL-17A, utilizing advanced technologies that enhance potency and extend the drug's half-life. Inmagene aims to create a new generation of therapeutics characterized by improved pharmacokinetics, pharmacodynamics, and safety profiles, which may lead to better efficacy and dosing convenience. With additional offices in Hangzhou and Beijing, Inmagene is committed to leveraging innovative resources and processes to facilitate drug development across borders, thereby enhancing the potential for positive patient outcomes worldwide.
Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.
XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders. Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve upon existing medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform.
XWPharma is a neuroscience biotech company that is researching new medicines for sleep, neuropsychiatric, and other neglected CNS illnesses. Bay Area, CA US.
Actym Therapeutics is a biotechnology company based in Berkeley, California, dedicated to developing innovative immuno-oncology therapies for cancer treatment. Founded in 2017, the company has created a unique therapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy), which uses an attenuated microbial approach to target solid tumors while sparing healthy tissue. This platform allows for the delivery of multiple immuno-modulatory payloads directly to immune cells residing within tumors, addressing challenges faced by traditional therapies. In preclinical studies, STACT has shown promise in enhancing treatment efficacy by engaging various biological pathways from a single therapy. The company successfully secured $34 million in a Series A financing round in April 2020, which was co-led by prominent venture funds, highlighting its potential in the biopharmaceutical landscape.
Human Longevity (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. Its business areas include the HLI Health Nucleus, a genomic powered clinical research center that uses whole-genome sequence analysis, advanced clinical imaging, and innovative machine learning, along with curated personal health information to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. It was founded in 2013 and is headquartered in San Diego, California.
TriArm Therapeutics is a cell therapy company established by Panacea Venture, with research and development operations in Germany, the United States, and the Greater China region. The company specializes in the research and clinical development of CD19 CAR-T products, utilizing non-viral gene transfer technology. This innovative approach significantly lowers both the cost and preparation time associated with cell therapy products, ultimately aiming to enhance therapeutic outcomes for cancer patients.
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.
OncXerna Therapeutics develops precision medicines for cancer patients by utilizing an innovative RNA-based biomarker platform that identifies patient responses based on the biology of their tumor microenvironments. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, the company aims to enhance patient care by matching individuals with clinical-stage therapies that specifically target their unique cancer biology. This approach allows OncXerna to provide potentially first-in-class oncology therapies, significantly improving patient outcomes. The company was previously known as Oncologie, Inc. before rebranding in September 2020.
Tactiva Therapeutics, LLC is a cancer immunotherapy company based in Buffalo, New York, founded in 2016. The company specializes in developing adoptive cell therapy, utilizing a dual T cell receptor approach to enhance treatment efficacy. Its platform includes engineered CD4 and CD8 T cells that not only provide direct anti-tumor activity but also support the function of CD8 T cell-derived effector cells. This innovative approach aims to create a durable supply of T cells that can effectively target and combat life-threatening cancers, enabling healthcare professionals to improve diagnosis and treatment outcomes for patients.
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.
BioGraph 55 is a biotechnology company specializing in immuno-oncology target discovery and drug development. The firm focuses on creating novel B-cell therapies to address critical unmet clinical needs in oncology and autoimmunity. Its services encompass the discovery and development of bispecific antibodies tailored for immuno-oncology and autoimmunity treatments. BioGraph 55 employs a reverse translational approach to identify potential cellular targets within diseased tissues and validate their mechanisms, enabling scientists to extract clinically relevant insights from the tumor microenvironment.